First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Trial Details

NCT ID
NCT05607498
Phase
PHASE1
Sponsor
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • EMB07
Locations (sample)
  • Frankston, Victoria, Australia|-38.14458,145.12291
  • Nedlands, Western Australia, Australia|-31.98184,115.8073
  • Changsha, Hunan, China|28.19874,112.97087
  • Baoding, China|38.87288,115.46246
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study p…
  • Male or female, and aged ≥ 18 years
  • Treatment group A: Patients with histologically or cytologically locally advanced unresectable or metastatic solid tumors limiting to triple-negati…
  • Treatment group A: Standard therapies do not exist, or are no longer effective, or are not tolerable or accessible to the patient measurable or eva…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →